52
Breaking news
Teva reported business records for the first quarter of 2022, down 8.06% in revenue to $ 3.66 billion, compared to revenue of $ 3.98 billion in the same quarter last year. It also posted a loss of $ 955 million compared to revenue of $ 77 million in the same quarter last year. The company’s president and CEO, Carr Schultz, said: “We have opened the year 2022 with the successful launch of the generic version of the drug REVLIMID and with an increase in our share of the AJOVY market, and a further increase in sales of AUSTEDO.”
Old John
03/05/2022 18:05